Dissonance in the face of Alzheimer's disease breakthroughs: clinician and lay stakeholder acceptance, concerns and willingness to pay for emerging disease-modifying therapies

CONCLUSIONS: This study exposes complex attitudes toward emerging DMTs for Alzheimer's disease, challenging conventional wisdom in multiple dimensions. A surprising 25% of the public expressed aversion to these new treatments, despite society's deep-rooted fear of dementia in older age. Healthcare professionals displayed nuanced concerns, prioritising clinical effectiveness and potential brain complications. Intriguingly, younger, better-educated and privately insured individuals exhibited a greater WTP, foregrounding critical questions about healthcare equity. These multifaceted findings serve as a guidepost for healthcare strategists, policymakers and ethicists as we edge closer to integrating DMTs into Alzheimer's disease care.PMID:38629297 | DOI:10.1192/bjp.2024.24

Source: The British Journal of Psychiatry for Mental Science - April 17, 2024 Category: Psychiatry Authors: Irina Kinchin Sharon Walsh Rachel Dinh Margaret Kapuwa Sean P Kennelly Ann-Marie Miller Ann Nolan Sean O'Dowd Laura O'Philbin Suzanne Timmons Iracema Leroi Source Type: research